Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

IAG flies higher after double upgrade to 'overweight' by JPMorgan

(Sharecast News) - BA and Iberia owner IAG flew higher on Wednesday as JPMorgan Cazenove double upgraded the shares to 'overweight' from 'underweight' and lifted the price target to €2.50 from €1.45. JPM said that previously, it had concerns that high capacity growth in 2024 would lead to pricing and earnings pressure.

"Whilst the shares have underperformed since our UW call, in our view, it's clear from the 2023 results that earnings are unlikely to decline this year," it said.

"We now see an opportunity for IAG to outperform consensus expectations despite the start of a re-investment cycle (higher opex/capex), which should then benefit longer-term earnings."

The bank said it now models flat unit revenues for 2024 and sits around 10% above Bloomberg consensus, with upside to estimates from strong leisure demand driving higher pricing.

It also noted that IAG is beginning a large re-investment cycle in 2024 which has the potential to drive sustainably higher EBIT margins from 2025 onwards.

JPM said British Airways EBIT is still around €500m below pre pandemic, with upside from capacity returning to 2019 levels and better operations/lower disruption costs.

Finally, it said that rapid de-leveraging has removed the pandemic balance sheet overhang and it forecasts "decent" free cash flow generation for 2024 despite high capex investment.

The bank lifted its 2024/25/26 EBIT estimates by 30%/33%/33% respectively, mostly due to higher revenues.

At 0900 GMT, the shares were up 4.7% at 148.50p.

Share this article

Related Sharecast Articles

Biome Technologies shares sink as Q1 sales drop 44%
(Sharecast News) - Shares in AIM-listed Biome Technologies plummeted by almost a third on Monday after the bioplastics and radio frequency technology business reported a poor start to the year with first-quarter sales dropping by 44%.
Entain reprices two term loans, revises interest cost outlook
(Sharecast News) - Betting and gambling giant Entain announced the successful repricing of two of its existing 'Term Loan B' loans on Monday, along with the pricing and allocation of fungible add-ons, in a bid to optimise its financial position.
Oxford Biomedica confident as it moves away from vaccine era
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation (CDMO) Oxford Biomedica reported stability in its core business on Monday, with a small increase in full-year core revenue for 2023, despite a 36% decrease in total revenue to £89.5m.
N Brown chairman Ron McMillan to retire
(Sharecast News) - N Brown said on Monday that chairman Ron McMillan will be retiring and stepping down from the board with effect from 30 April for personal reasons.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.